Skip to main content

Advertisement

SpringerLink
Log in

Preventing vertical virus infections: the role of serologic screening of pregnant women

  • Review
  • Published:
Medical Microbiology and Immunology Aims and scope Submit manuscript

Abstract

Several virus infections affect the pregnancy itself as well as the foetal development (rubella, PVB19, VZV, HSV, HCMV, HBV, HIV). Prevention can be established by vaccination or an assessment of the immunity status as well as by chemotherapy. The following review provides an update to current aspects focusing on the role of serologic screening.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. WHO Fact Sheet Rubella, updated November 2017. http://www.who.int/en/news-room/fact-sheets/detail/rubella. Accessed 3 Jul 2018

  2. Vauloup-Fellous C (2018) Standardization of rubella immunoassays. J Clin Virol 102:34–38

    Article  CAS  Google Scholar 

  3. Robert-Koch-Institut (2010) Änderung der Empfehlungen zur Impfung gegen Röteln. Epidemiol Bull 32:322–325. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2010/Ausgaben/32_10.pdf?__blob=publicationFile. Accessed 3 Jul 2018

  4. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Leitlinie: Labordiagnostik schwangerschaftsrelevanter Virusinfektionen. S2k-Leitlinie AWMF Registernummer 0093/001 Stand: 31.03.2014. http://www.awmf.org/leitlinien/detail/ll/093-001.html. Accessed 12 Feb 2018

  5. Bonvicini F. Bua G, Gallinella G (2017) Parvovirus B19 infection in pregnancy-awareness and opportunities. Curr Opin Virol 27:8–14

    Article  Google Scholar 

  6. Public Health Laboratory Service Working Party on Fifth Disease (1990) Prospective study of human parvovirus (B19) infection in pregnancy. BMJ 300:1166–1170

    Article  Google Scholar 

  7. Rodis JF, Quinn DL, Gary GW Jr, Anderson LJ (1990) Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am J Obstet Gynecol 163:1168–1171

    Article  CAS  Google Scholar 

  8. Reinheimer C, Allwinn R, Doerr HW, Wittek M (2010) Seroepidemiology of parvovirus B19 in the Frankfurt am Main area, Germany: evaluation of risk factors. Infection 38:381–385

    Article  CAS  Google Scholar 

  9. Barlinn R, Rollag H, Trogstad L et al (2017) High incidence of maternal parvovirus B19 infection in a large unselected population-based pregnancy cohort in Norway. J Clin Virol 94:57–62

    Article  Google Scholar 

  10. Bredl S, Plentz A, Wenzel JJ, Pfister H, Möst J, Modrow S (2011) False-negative serology in patients with acute parvovirus B19 infection. J Clin Virol 51:115–120

    Article  Google Scholar 

  11. Crane J, Mundle W, Boucoiran I et al (2014) Parvovirus B19 in pregnancy. J Obstet Gynaecol Can 36:1107–1116

    Article  Google Scholar 

  12. Matsuda H, Sakaguchi K, Shibasaki T, Takahashi H, Kawakami Y, Furuya K (2005) Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J Perinat Med 33:561–563

    Google Scholar 

  13. Pasternak B, Hviid A (2010) Use of acyclovir, valacyclovir and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 304:859–866

    Article  CAS  Google Scholar 

  14. Sauerbrei A, Wutzler P (2007) Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 2: varicella-zoster virus infections. Med Microbiol Immunol 196:95–102

    Article  CAS  Google Scholar 

  15. Wiese-Posselt M, Siedler A, Mankertz A et al (2017) Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany. BMC Infect Dis 17:356

    Article  Google Scholar 

  16. Werner RN, Nikkels AF, Marinović B et al (2017) European consensus-based (S2k) guideline on the management of herpes zoster—guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 1: diagnosis. J Eur Acad Dermatol Venereol 31:9–19

    Article  CAS  Google Scholar 

  17. Doerr HW (2013) Progress in VZV vaccination? Some concerns. Med Microbiol Immunol 202:257–258

    Article  CAS  Google Scholar 

  18. Wicker S, Rabenau HF, Gottschalk R, Doerr HW, Allwinn R (2007) Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, VZV, polio, HBV, HCV and HIV) in medical students. Med Microbiol Immunol 196:145–150

    Article  Google Scholar 

  19. Wittek M, Doerr HW, Allwinn R (2010) Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics. Med Klin (Munich) 105:334–338

    Article  Google Scholar 

  20. Buxbaum S, Geers M, Gross G, Schöfer H, Rabenau HF, Doerr HW (2003) Epidemiology of herpes simplex virus types 1 and 2 in Germany: what has changed? Med Microbiol Immunol 192:177–181

    Article  CAS  Google Scholar 

  21. Gupta R, Warren T, Wald A (2007) Genital herpes. Lancet 370:2127–2137

    Article  Google Scholar 

  22. Kimberlin D (2004) Neonatal herpes simplex infection. Clin Microbiol Rev 17(1):1–13

    Article  Google Scholar 

  23. Hollier LM, Wendel GD (2008) Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev 1:CD004946

    Google Scholar 

  24. Pichler M, Staffler A, Bonometti N, Messner H, Deluca J, Thuile T, Kluge R, Schmuth M, Eisendle K (2015) Premature newborns with fatal intrauterine herpes simplex virus-1 infection: first report of twins and review of the literature. J Eur Acad Dermatol Venereol 29:1216–1220

    Article  CAS  Google Scholar 

  25. Doerr HW, Berger A (2014) Vaccination against infectious diseases. What is promising? Med Microbiol Immunol 203:365–371

    Article  CAS  Google Scholar 

  26. Lübeck PR, Doerr HW, Rabenau HF (2010) Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: what has changed? Med Microbiol Immunol 199:53–60

    Article  Google Scholar 

  27. Enders G, Daiminger A, Lindemann L, Knotek F, Bäder U, Exler S, Enders M (2012) Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996–2010. Med Microbiol Immunol 201:303–309

    Article  Google Scholar 

  28. Rycel M, Wujcicka W, Zawilińska B, Paradowska E, Suski P, Gaj Z, Wilczyński J, Leśnikowski Z, Nowakowska D (2015) Mixed infections with distinct cytomegalovirus glycoprotein B genotypes in Polish pregnant women, foetuses, and newborns. Eur J Clin Microbiol Infect Dis 34:585–591

    Article  CAS  Google Scholar 

  29. Kagan KO, Hamprecht K (2017) Cytomegalovirus in pregnancy. Arch Gynecol Obstet 296:15–26

    Article  Google Scholar 

  30. Doerr HW (1987) Cytomegalovirus infection in pregnancy. J Virol Methods 17:127–132

    Article  CAS  Google Scholar 

  31. Britt W (2015) Controversies in the natural history of congenital human cytomegalovirus infection: the paradox of infection and disease in offspring of women with immunity prior to pregnancy. Med Microbiol Immunol 204:263–271

    Article  CAS  Google Scholar 

  32. Berger A, Reitter A, Harter PN, Buxmann H, Allwinn R, Louwen F, Doerr HW (2011) Problems and challenges in the diagnosis of vertical infection with human cytomegalovirus (CMV): lessons from two accidental cases. J Clin Virol 51:285–288

    Article  Google Scholar 

  33. Doerr HW (2016) Fighting cytomegalovirus-caused diseases: the immunologic approach. Med Microbiol Immunol 205:511–512

    Article  CAS  Google Scholar 

  34. Lanzieri TM, Dollard SC, Josephson CD, Schmid DS, Bialek SR (2013) Breast milk-acquired cytomegalovirus infection and disease in very low birth weight and premature infants. Pediatrics 131(6):e1937–e1945

    Article  Google Scholar 

  35. Reitter A, Buxmann H, Haberl AE, Schlösser R, Kreibich M, Keppler OT, Berger A (2016) Incidence of CMV co-infection in HIV-positive women and their neonates in a tertiary referral centre: a cohort study. Med Microbiol Immunol 205:63–71

    Article  CAS  Google Scholar 

  36. Wagner N, Kagan KO, Haen S, Schmidt S et al (2014) Effective management and intrauterine treatment of congenital cytomegalovirus infection: review article and case series. J Matern Fetal Neonatal Med 27:209–214

    Article  Google Scholar 

  37. Seidel V, Feiterna-Sperling C, Siedentopf JP, Hofmann J et al (2017) Intrauterine therapy of cytomegalovirus infection with valganciclovir: review of the literature. Med Microbiol Immunol 206:347–354

    Article  CAS  Google Scholar 

  38. Rawlinson W (2017) Congenital CMV international guidelines are needed to guide diagnosis, prevention and management. Acta Paediatr 106(9):1389–1390

    Article  Google Scholar 

  39. Hamprecht K, Kagan KO, Schampera M, Jahn G (2018) Impact of pharmacokinetics on the efficiency of CMV-specific hyperimmune globulin treatment in early CMV-primary infection during pregnancy (abstract). In: 28th annual meeting of the Society for Virology, March 14–17, Würzburg, OP 137

  40. Plotkin S (2015) The history of vaccination against cytomegalovirus. Med Microbiol Immunol 204:247–254

    Article  CAS  Google Scholar 

  41. Mocarski ES (2015) Stanley Plotkin: the bright spark of cytomegalovirus vaccines. Med Microbiol Immunol 204:243–245

    Article  Google Scholar 

  42. Plachter B (2016) Prospects a vaccine for the prevention of congenital cytomegalovirus disease. Med Microbiol Immunol 205:537–547

    Article  CAS  Google Scholar 

  43. Mavilia MG, Wu GY (2017) Mechanisms and prevention of vertical transmission in chronic viral hepatitis. J Clin Transl Hepatol 5:119–129 (Review)

    Article  Google Scholar 

  44. Nakagawa F, Phillips AN, Lundgren JD (2014) Update on HIV in Western Europe. Curr HIV/AIDS Rep 11:177–185 (Review)

    Article  Google Scholar 

  45. Vrazo AC, Firth J, Amzel A, Sedillo R, Ryan J, Phelps BR (2018) Interventions to significantly improve service uptake and retention of HIV-positive pregnant women and HIV-exposed infants along the PMTCT continuum of care. A systematic review. Trop Med Int Health 23:136–148

    Article  Google Scholar 

  46. Park JS, Pan CQ (2017) Viral factors for HBV mother-to-child transmission. Hepatol Int 11:476–480

    Article  Google Scholar 

  47. Weis N, Cowan S, Hallager S, Dröse S et al (2017) Vertical transmission of hepatitis B virus during pregnancy and delivery in Denmark. Scand J Gastroenterol 52:178–184

    Article  CAS  Google Scholar 

  48. Tavakolpour S, Darvishi M, Mirsafaei HS, Ghasemiadl M (2018) Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review. Infect Dis (Lond) 50:95–106

    CAS  Google Scholar 

  49. Gerlich WH (2015) Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol 204:39–55

    Article  CAS  Google Scholar 

  50. Shouval D. Roggendorf H, Roggendorf M (2015) Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol 204:57–68

    Article  CAS  Google Scholar 

  51. Doerr HW (2013) Perspectives of vaccination in adults. Expert Rev Vaccines 12:593–596

    Article  CAS  Google Scholar 

  52. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S2k Leitlinie: Deutsch-Österreichische Leitlinie zur HIV-Therapie in der Schwangerschaft und bei HIVexponierten Neugeborenen. AWMF-Register-Nr.: 055-002 Stand März 2017. http://www.awmf.org/uploads/tx_szleitlinien/055-002l_S2k_HIV-Therapie_Schwangerschaft_Neugeborenen_2017-07.pdf. Accessed 3 Jul 2018

  53. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S2k Leitlinie: Leitlinien zur antiretroviralen Therapie bei Kindern und Jugendlichen. AWMF-Register-Nr.: 048-011 Klassifikation: S1 Version 03_2013 Stand 17.03.2013. http://www.awmf.org/uploads/tx_szleitlinien/048-011l_S1_Antiretroviralen_Therapie_bei_Kindern_und_Jugendlichen_03-2013-abgelaufen.pdf. Accessed 3 Jul 2018

Download references

Acknowledgements

We greatly thank Andrea Doerr for editing the manuscript.

Author information

Authors and Affiliations

  1. Institut für Medizinische Virologie, Universitätsklinikum Frankfurt, Goethe Universität, Paul Ehrlich Str. 40, 60596, Frankfurt, Germany

    Annemarie Berger & Hans Wilhelm Doerr

Authors
  1. Annemarie Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans Wilhelm Doerr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annemarie Berger.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berger, A., Doerr, H.W. Preventing vertical virus infections: the role of serologic screening of pregnant women. Med Microbiol Immunol 207, 249–253 (2018). https://doi.org/10.1007/s00430-018-0549-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00430-018-0549-y

Keywords

Search

Navigation